Market overview
The global oncolytic virus cancer therapy market is worth USD 342 mn in 2026 and is forecast to reach USD 2.1 bn by 2036, growing at a 20.0% CAGR. United States is the largest country market and Intravesical adenoviral vectors is the largest by product segment.
| Scope | Replicating and engineered viruses used to treat cancer, including approved oncolytic virus products and viral-vector bladder cancer therapies sold to hospitals and specialty pharmacies. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 280 mn |
| Value 2026 | USD 342 mn |
| Value 2036 | USD 2.1 bn |
| CAGR 2026-2036 | 20.0% |
| Volume 2026 | 24.6 thousand doses |
| Volume 2036 | 169 thousand doses |
| Average price 2026 | USD 13,860 per dose |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Oncolytic Virus Cancer Therapy market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 342 mn |
| 2027 | USD 410 mn |
| 2028 | USD 492 mn |
| 2029 | USD 590 mn |
| 2030 | USD 708 mn |
| 2031 | USD 850 mn |
| 2032 | USD 1.0 bn |
| 2033 | USD 1.2 bn |
| 2034 | USD 1.5 bn |
| 2035 | USD 1.8 bn |
| 2036 | USD 2.1 bn |
Oncolytic Virus Cancer Therapy market segmentation
By product
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Talimogene laherparepvec | 25.0% | 6.9% | USD 85 mn | 5.5% |
| Intravesical adenoviral vectors | 52.0% | 61.3% | USD 178 mn | 22.0% |
| Regional oncolytic products | 13.0% | 5.2% | USD 44 mn | 9.6% |
| New launches | 10.0% | 26.6% | USD 34 mn | 32.3% |
By cancer type
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Melanoma | 26.0% | 6.8% | USD 89 mn | 4.9% |
| Bladder | 54.0% | 63.3% | USD 184 mn | 21.9% |
| Head and neck and other | 20.0% | 29.9% | USD 68 mn | 24.9% |
By virus platform
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Herpes simplex virus | 44.0% | 40.0% | USD 150 mn | 18.9% |
| Adenovirus | 22.0% | 22.0% | USD 75 mn | 20.0% |
| Vaccinia and poxvirus | 14.0% | 15.0% | USD 48 mn | 20.8% |
| Reovirus and others | 20.0% | 23.0% | USD 68 mn | 21.7% |
By combination
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Monotherapy | 44.0% | 34.0% | USD 150 mn | 16.9% |
| Combined with checkpoint inhibitors | 42.0% | 48.0% | USD 143 mn | 21.6% |
| Combined with chemotherapy or radiation | 14.0% | 18.0% | USD 48 mn | 23.1% |
By route of delivery
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Intratumoral injection | 70.0% | 62.0% | USD 239 mn | 18.6% |
| Intravenous | 20.0% | 25.0% | USD 68 mn | 22.7% |
| Intravesical and other | 10.0% | 13.0% | USD 34 mn | 23.2% |
Top 25 countries for oncolytic virus cancer therapy by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 99.0% of 2026 revenue and the 25 countries below together hold 99.7%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 212 mn | 62.0% | USD 1.3 bn | 20.2% |
| 2 | Japan | USD 31 mn | 9.0% | USD 127 mn | 15.2% |
| 3 | China | USD 24 mn | 7.0% | USD 150 mn | 20.2% |
| 4 | Germany | USD 17 mn | 5.0% | USD 116 mn | 21.1% |
| 5 | France | USD 12 mn | 3.5% | USD 82 mn | 21.3% |
| 6 | United Kingdom | USD 12 mn | 3.5% | USD 82 mn | 21.3% |
| 7 | Italy | USD 8.5 mn | 2.5% | USD 59 mn | 21.4% |
| 8 | Canada | USD 8.5 mn | 2.5% | USD 53 mn | 20.0% |
| 9 | Spain | USD 6.8 mn | 2.0% | USD 47 mn | 21.1% |
| 10 | Australia | USD 6.8 mn | 2.0% | USD 42 mn | 20.0% |
| 11 | Mexico | USD 0.44 mn | 0.1% | USD 2.5 mn | 19.0% |
| 12 | Netherlands | USD 0.38 mn | 0.1% | USD 2.1 mn | 18.9% |
| 13 | South Korea | USD 0.27 mn | 0.08% | USD 1.7 mn | 20.0% |
| 14 | Switzerland | USD 0.24 mn | 0.07% | USD 1.3 mn | 18.2% |
| 15 | Belgium | USD 0.20 mn | 0.06% | USD 1.1 mn | 17.8% |
| 16 | Denmark | USD 0.17 mn | 0.05% | USD 1.1 mn | 20.0% |
| 17 | Sweden | USD 0.14 mn | 0.04% | USD 0.85 mn | 20.0% |
| 18 | Austria | USD 0.10 mn | 0.03% | USD 0.63 mn | 20.0% |
| 19 | Israel | USD 0.10 mn | 0.03% | USD 0.63 mn | 20.0% |
| 20 | Taiwan | USD 68 thousand | 0.02% | USD 0.42 mn | 20.0% |
| 21 | Brazil | USD 68 thousand | 0.02% | USD 0.42 mn | 20.0% |
| 22 | Singapore | USD 68 thousand | 0.02% | USD 0.21 mn | 12.0% |
| 23 | Poland | USD 34 thousand | 0.01% | USD 0.21 mn | 20.0% |
| 24 | Norway | USD 34 thousand | 0.01% | USD 0.21 mn | 20.0% |
| 25 | Turkey | USD 34 thousand | 0.01% | USD 0.21 mn | 20.0% |
| Rest of world | USD 1.1 mn | 0.3% | USD 5.5 mn | 17.9% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Amgen
- Ferring Pharmaceuticals
- Daiichi Sankyo
Group 2: Regional and specialist players
- Shanghai Sunway Biotech
- CG Oncology
- Candel Therapeutics
Group 3: Emerging and niche players
- Replimune
- Oncolytics Biotech
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the oncolytic virus cancer therapy market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 20.0% is calculated from the resulting values.
The market is divided by product, by cancer type, by virus platform, by combination, by route of delivery. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the oncolytic virus cancer therapy market?
The global oncolytic virus cancer therapy market is estimated at USD 280 mn in 2025 and USD 342 mn in 2026.
How fast will the oncolytic virus cancer therapy market grow?
It is forecast to reach USD 2.1 bn by 2036, a compound annual growth rate of 20.0% from 2026, an increase of USD 1.8 bn.
Which country is the largest market for oncolytic virus cancer therapy?
United States is the largest market by revenue at USD 212 mn in 2026, 62.0% of the global total. The three largest countries together hold 78.0%.
Which country is growing fastest?
Among the ten largest markets, Italy is growing fastest at 21.4% a year from 2026 to 2036.
Which oncolytic virus cancer therapy segment is largest?
In the by product split, Intravesical adenoviral vectors is the largest segment with 52.0% of 2026 revenue.
Who are the leading oncolytic virus cancer therapy companies?
Global leaders include Amgen, Ferring Pharmaceuticals, Daiichi Sankyo.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Lactation Nutrition ProductsUSD 342 mn · 6.5% CAGR
- Closed-Loop Centesis SystemsUSD 341 mn · 6.5% CAGR
- MRI-based Quantitative BiomarkersUSD 348 mn · 15.0% CAGR
- Dental AutoclavesUSD 355 mn · 4.5% CAGR
- Adaptive StrollerUSD 362 mn · 6.0% CAGR
- Veterinary Allergy DiagnosticsUSD 321 mn · 6.5% CAGR
- Kidney Transplant Rejection BiomarkerUSD 319 mn · 9.0% CAGR
- Smart Breast ImagingUSD 366 mn · 19.0% CAGR